Search

Your search keyword '"A. Juan-Mas"' showing total 241 results
Start Over Author "A. Juan-Mas"
241 results on '"A. Juan-Mas"'

1. Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes

Author

Aterido, Adrià, López-Lasanta, María, Blanco, Francisco, Juan-Mas, Antonio, García-Vivar, María Luz, Erra, Alba, Pérez-García, Carolina, Sánchez-Fernández, Simón Ángel, Sanmartí, Raimon, Fernández-Nebro, Antonio, Alperi-López, Mercedes, Tornero, Jesús, Ortiz, Ana María, Fernández-Cid, Carlos Marras, Palau, Núria, Pan, Wenjing, Byrne-Steele, Miranda, Starenki, Dmytro, Weber, Daniel, Rodriguez-Nunez, Ivan, Han, Jian, Myers, Richard M., Marsal, Sara, and Julià, Antonio

Published
2024
Full Text
View/download PDF

2. Osseous sarcoidosis presenting as lytic and blastic bone lesions: A rare diagnostic challenge

Author

J. Bastidas, L. López-Nuñez, R. Faré, Javier G. Moríñigo, I. Ros, and A. Juan Mas

Subjects
Sarcoidosis, Osseous bone lesions, Granuloma, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Osseous sarcoidosis is a rare manifestation of sarcoidosis, often mimicking other conditions like metastatic disease. Skeletal involvement occurs in only 3%-13% of cases (1), making diagnosis challenging. We present the case of a 63-year-old female with a 1-month history of inflammatory bone pain and multiple lytic and blastic lesions.A 63-year-old female presented with a 1-month history of inflammatory pain in the left hip and lumbar spine. Radiological studies, including magnetic resonance imaging (MRI) and computed tomography (CT), revealed multiple bone lesions throughout the lumbar spine, sacrum and iliac bones, raising suspicion of metastatic disease a bone biopsy confirmed a diagnosis of sarcoidosis.MRI and CT showed lytic and blastic lesions in the axial skeleton, with FDG-PET indicating diffuse uptake in the iliac bone and mediastinal adenopathy. Imaging was crucial in ruling out metastases and guiding the biopsy, which confirmed the diagnosis.Osseous sarcoidosis is a rare entity that poses a significant diagnostic challenge, often resembling metastatic disease. Imaging techniques such as MRI and CT, combined with biopsy, are effective, noninvasive methods for evaluation and diagnosis. The patient was treated with corticosteroids in high doses and systemic methotrexate, showing improvement in inflammatory pain and stabilization of the bone lesions.

Published
2025
Full Text
View/download PDF

3. Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry

Author

Juan Molina-Collada, Marta Domínguez-Álvaro, Rafael B. Melero-González, Eugenio de Miguel, Maite Silva-Díaz, Jesús Alejandro Valero Jaimes, Ismael González, Julio Sánchez Martín, Javier Narváez, Joan Calvet, Ivette Casafont-Solé, Jose A Román Ivorra, Selene Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María Sagrario Bustabad Reyes, Cristina Campos Fernández, María Alcalde Villar, Antonio Juan Mas, Ricardo Blanco, and on behalf of the ARTESER Project Collaborative Group

Subjects
Mortality, Survival, Giant cell arteritis, Vasculitis, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Objectives To compare mortality rates between GCA patients and the general population in Spain, and to identify associated factors influencing mortality. Methods ARTESER, a multicenter registry by the Spanish Society of Rheumatology, includes GCA patients from June 2013 to March 2019. Demographic, clinical, imaging, histological and mortality data were collected retrospectively. Only patients with at least one year of follow-up were included for analysis. The mortality rates were expressed as the number of deaths per 1000 person-years, with 95% confidence interval (CI) by sex and age group. Kaplan-Meier method was performed for survival analysis. The factors influencing mortality were analyzed using Cox regression model. Results A total of 1200 patients with GCA were analyzed, with a mean (SD) follow-up of 2.18 (1.53) years. The overall five-year cumulative mortality rate (95%CI) was 37.86 (31.75-43.96) per 1000 patients/year. The cumulative mortality rate was significantly higher in males than females (59.04vs29.06; p

Published
2025
Full Text
View/download PDF

4. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry

Author

Tatiana Cobo-Ibáñez, Ivan Castellví, Ana Pros, Marta Domínguez-Álvaro, Laura Nuño-Nuño, Julia Martínez-Barrio, Vega Jovaní, Fredeswinda Romero-Bueno, Esther Ruiz-Lucea, Eva Tomero, Ernesto Trallero-Araguás, Javier Narváez, Jordi Camins-Fàbregas, Alberto Ruiz-Román, Jesús Loarce-Martos, Susana Holgado-Pérez, V Miguel Flores-Rodríguez, Francisca Sivera, Carolina Merino-Argumanez, Antonio Juan-Mas, Irene Altabás-González, María Martín-López, Joaquín María Belzunegui-Otano, Carmen Carrasco-Cubero, Mercedes Freire-González, Iñigo Rúa-Figueroa, Nuria Lozano-Rivas, Julio David Suarez-Cuba, Olga Martínez, Rafaela Ortega-Castro, Patricia Alcocer, Alejandro Gómez-Gómez, Olga Sánchez-Pernaute, José Luis Tandaipan, Irene Carrión-Barberà, Chamaida Plasencia-Rodríguez, Oihane Ibarguengoitia-Barrena, Paola Vidal-Montal, Vera Ortiz-Santamaria, Noemi Garrido-Puñal, Anne Riveros, Esmeralda Delgado-Frías, Juan Miguel López-Gómez, Carmen Barbadillo, José María Pego-Reigosa, Beatriz E. Joven-Ibáñez, Jesús Alejandro Valero-Jaimes, Elena Naveda, Ana Isabel Turrión-Nieves, Daniel Seoane-Mato, Francisco Javier Prado-Galbarro, and M Ángeles Puche-Larrubia

Subjects
Idiopathic inflammatory myopathies, Antisynthetase, Autoantibodies, Activity, Damage, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Objective To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Methods Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. Results A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p

Published
2025
Full Text
View/download PDF

5. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

Author

Jesús Tornero, Alba Erra, Santos Castañeda, Carolina Pérez-García, Raimon Sanmartí, Sara Marsal, Ingrid Moller, Esperanza Naredo, Miguel A González-Gay, Celia Erausquin, Ivan Castellví, Javier Llorca, Alejandro Muñoz, María Galindo, Enrique Raya, Lydia Abasolo, Gema Bonilla, Alfonso Corrales, Inmaculada Ureña, Carlos Rodríguez-Lozano, Carlos González-Juanatey, Cristina Fernandez Carballido, Francisco J López-Longo, Miguel Ángel González-Gay, Eduardo Collantes, José A Miranda-Filloy, Sagrario Bustabad, Indalecio Monteagudo, Jose A Piqueras, Tatiana Cobo, Joan Maymó, Carmen Barbadillo, Soledad Ojeda, Jaime Calvo Alen, Antonio Fernandez Nebro, Isabel Rodríguez, Pilar Font, Martina Steiner, Eugenio Chamizo Carmona, Beatriz González Álvarez, Santiago Munoz, Joan M Nolla, Fernando Sánchez-Alonso, Julio Sanchez, Raul Menor Almagro, Ana Pérez Gómez, Monica Ibañez, Elena Heras-Recuero, Trinidad Pérez Sandoval, Miren Uriarte-Ecenarro, Angela Pecondón, Hye Sang Park, Jessica Polo y La Borda, Zulema Plaza, Carmen García Gómez, Ivan Ferraz-Amaro, Jesús Tomás Sanchez-Costa, Olga Carmen Sánchez-González, Ana Isabel Turrión-Nieves, Ana Perez-Alcalá, José L FernándezSueiro, José A Pinto-Tasende, Eugenia Gonzálezde Rábago, María J González-Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol, Gabriela Ávila, Cayetano Alegre, Fernando Gamero, José García Torón, María P Moreno-Gil, Antonio Juan-Mas, Pilar Espiño, Inmaculada Ros, Horacio Berman, Oscar Fontseré Patón, Benjamín Fernández Gutiérrez, José M Pina-Salvador, María D Fábregas, Montserrat Romera, Jesús A García-Vadillo, Rosario García de Vicuña, María A Belmonte, María V Irigoyen, Olga Martínez González, Rebeca Belmonte Gómez, Pastora Granados Bautista, Azucena Hernández Sanz, José Santos Rey, Carmen O Sánchez-González, Javier Bachiller, Antonio Zea, Francisco J Manero, Chesús Beltrán Audera, Marta Medrano, Jesús Babío Herráez, Javier del Pino, Ruth López González, María Enriqueta Peiró, José M Senabre, José C Rosas, Isabel Rotés, Estefanía Moreno, Javier Calvo, Amalia Rueda, Pilar Morales, Ana Nieto, Ana Ruibal Escribano, Sergio Ros Expósito, Ginés Sánchez Nievas, Enrique Júdez Navarro, Manuela Sianes Fernández, Silvia Martínez Pardo, Manel Pujol, Alberto Cantabrana, Esmeralda Delgado, Sergio Rodríguez Montero, Javier Rivera Redondo, Teresa González Hernández, Francisco J González-Polo, José M Moreno, Emilio Giner Serret, Laura Cebrián Méndez, María Teresa Navío, Teresa Pedraz Penalva, Encarnación Pagán, Pablo Mesadel Castillo, Ana Cruz, Ana Turrión, Desireé Ruíz, Antonio López Meseguer, Manuel J Moreno, Luis F Linares, Mercedes Morcillo, María L González-Gómez, José M Aramburu, Natalia A Rivera, Olaia Fernández Berrizbeitia, Manel Riera, Yolanda María León, Miriam Amirall, Jordi Fiter, Julia Fernández Melón, Luis Espadaler, Joaquín Belzunegui, Inmaculada Bañegil, César Díaz, Ramón Valls, María Bonet, Eva Revuelta Evrard, Javier R Godo, and José A González-Fernández

Subjects
Medicine
Abstract

Objective To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients.Methods Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics at tertiary centres for 7.5 years, were retrospectively analysed to test the performance of the Systematic Coronary Risk Assessment (SCORE), the modified version (mSCORE) European Alliance of Rheumatology Associations (EULAR) 2015/2016, the SCORE2 algorithm (the updated and improved version of SCORE) and the QRESEARCH risk estimator version 3 (QRISK3).Results Over 4790 years of follow-up, there were 34 CV events, resulting in a linearised rate of 7.10 per 1000 person-years (95% CI 4.92 to 9.92). The four CV risk scales showed strong correlations and all showed significant associations with CV events (p

Published
2024
Full Text
View/download PDF

6. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study

Author

Cesar Díaz-Torné, Virginia Ruiz-Esquide, Clementina López-Medina, Alejandro Balsa, Alejandro Escudero-Contreras, Rafaela Ortega-Castro, Sara Manrique-Arija, Chamaida Plasencia-Rodríguez, Natalia Mena-Vazquez, Ana Martínez-Feito, Jerusalem Calvo-Gutiérrez, M Carmen Ábalos-Aguilera, Francisco Cepas, Regina Faré-García, Antoni Juan-Mas, Luis Sainz, Francisco Javier Godoy-Navarrete, Isabel Añón-Oñate, and Marina Soledad Moreno-García

Subjects
Medicine
Abstract

Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels.Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off:

Published
2024
Full Text
View/download PDF

7. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

Author

Santos Castañeda, Ricardo Blanco, Héctor Corominas, Patricia Carreira, Ivan Castellví, Eugenio De Miguel, Javier Narváez, Judit LLuch, Ivette Casafont-Solé, Jose María Pego, Lydia Abasolo, Carmen Larena, Francisco Ortiz-Sanjuán, Clara Moriano Morales, Elvira Díez Álvarez, Miguel Ángel González-Gay, Berta Magallares, Monica Ibañez Barcelo, Laura Garrido Courel, Vanesa Hernandez Hernandez, Patricia Moya Alvarado, Anne Riveros Frutos, Margarida Vasques Rocha, María Alcalde Villar, Antonio Juan Mas, Julio Sanchez, Joan Calvet, Clara Molina Almela, Amalia Rueda Cid, Cristina Campos Fernández, Carmen Riesco Bárcena, Patricia Moran Alvarez, Judit Font Urgelles, Alejandro Muñoz Jiménez, Delia Fernández-Lozano, Iñigo Hernández-Rodríguez, Marta Domínguez-Álvaro, Maite Silva-Díaz, Joaquín María Belzunegui, Eva Galíndez-Agirregoikoa, Vicente Aldaroso, Javier Loricera, Noemi Garrido-Puñal, Vanessa Andrea Navarro, Tarek Carlos Salman Monte, Trinidad Pérez Sandoval, Ismael González Fernández, Javier Mendizábal-Mateos, María Concepción Fito Manteca, Natividad del Val del Amo, Loreto Horcada Rubio, Inmaculada Paniagua Zudaire, Ricardo Gutiérrez Polo, Juliana Restrepo Vélez, Eduardo Loza Cortina, Elisa Fernández Fernández, Tomás Almorza, Leticia Léon Mateos, Luis Rodríguez Rodríguez, Pia Mercedes Lois Bermejo, Selene Labrada Arrabal, Susana Holgado Pérez, Jordi Camins, Javier Calvo Catalá, Rafael Benito Melero, Francisco Maceiras, Nair Pérez, Ceferino Barbazán, Irena Altabás, John Guzman, Paula Valentina Estrada Alarcón, Ana Milena Millán, AnaF Cruz Valenciano, Félix Cabero del Pozo, AnaBelén Rodríguez Cambrón, Cristina Macia Villa, Inmaculada Ros Vilamajó, Elide Toniolo, Ana Paula Cacheda, María Sagrario Bustabad Reyes, María García González, Alicia García Dorta, Jaime Calvo Allen, Miren Uriarte-Ecenarro, Cristina Valero Martínez, Esther F Vicente Rabaneda, Carlos García Porrúa, Carlota Laura Iñiguez Ubiaga, Noelia Álvarez Rivas, Tomás Ramón Vázquez Rodríguez, José Alberto Miranda Filloy, Amalia Sánchez-Andrade Fernández, Carlos Galisteo Lencastre Da Veiga, María Jesús García Villanueva, Marina Tortosa Cabañas, Marta Serrano Warleta, Aliuska Palomeque Vargas, Alberto Ruiz Román, Clara Aguilera Cros, JoséA Román Ivorra, Anderson Huaylla, Itziar Calvo Zorrilla, Jesús A Valero-Jaimes, Luis López Domínguez, Cesar Antonio Egues Dubuc, and Lucia Silva Fernández

Subjects
Medicine
Abstract

Objective This study aimed to estimate the incidence of giant cell arteritis (GCA) in Spain and to analyse its clinical manifestations, and distribution by age group, sex, geographical area and season.Methods We included all patients diagnosed with GCA between 1 June 2013 and 29 March 2019 at 26 hospitals of the National Health System. They had to be aged ≥50 years and have at least one positive results in an objective diagnostic test (biopsy or imaging techniques), meet 3/5 of the 1990 American College of Rheumatology classification criteria or have a clinical diagnosis based on the expert opinion of the physician in charge. We calculated incidence rate using Poisson regression and assessed the influence of age, sex, geographical area and season.Results We identified 1675 cases of GCA with a mean age at diagnosis of 76.9±8.3 years. The annual incidence was estimated at 7.42 (95% CI 6.57 to 8.27) cases of GCA per 100 000 people ≥50 years with a peak for patients aged 80–84 years (23.06 (95% CI 20.89 to 25.4)). The incidence was greater in women (10.06 (95% CI 8.7 to 11.5)) than in men (4.83 (95% CI 3.8 to 5.9)). No significant differences were found between geographical distribution and incidence throughout the year (p=0.125). The phenotypes at diagnosis were cranial in 1091 patients, extracranial in 337 patients and mixed in 170 patients.Conclusions This is the first study to estimate the incidence of GCA in Spain at a national level. We found a predominance among women and during the ninth decade of life with no clear variability according to geographical area or seasons of the year.

Published
2024
Full Text
View/download PDF

8. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

Author

Silva-Díaz, Maite, Blanco, Francisco J., Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez-Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Prado-Galbarro, Francisco Javier, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2022
Full Text
View/download PDF

9. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry.

Author

Cobo-Ibáñez, Tatiana, Castellví, Ivan, Pros, Ana, Domínguez-Álvaro, Marta, Nuño-Nuño, Laura, Martínez-Barrio, Julia, Jovaní, Vega, Romero-Bueno, Fredeswinda, Ruiz-Lucea, Esther, Tomero, Eva, Trallero-Araguás, Ernesto, Narváez, Javier, Camins-Fàbregas, Jordi, Ruiz-Román, Alberto, Loarce-Martos, Jesús, Holgado-Pérez, Susana, Flores-Rodríguez, V Miguel, Sivera, Francisca, Merino-Argumanez, Carolina, and Juan-Mas, Antonio

Published
2025
Full Text
View/download PDF

10. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*

Author

Blanco, Francisco J., Silva-Díaz, Maite, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2021
Full Text
View/download PDF

11. Prevalencia de artrosis sintomática en España: Estudio EPISER2016

Author

Blanco, Francisco J., Silva-Díaz, Maite, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2021
Full Text
View/download PDF

12. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register

Author

Ricardo Blanco, Miguel A González-Gay, Alejandro Muñoz, María Jesús García-Villanueva, Jesús T Sanchez-Costa, Paula Estrada, Cristina Valero Martínez, Patricia Moya Alvarado, Vanessa A Navarro Angeles, Carlos Galisteo Lencastre Da Veiga, Anne Riveros Frutos, Jose A Román Ivorra, Selena Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María García-Gonzalez, María Alcalde Villar, Antonio Juan Mas, and Clara Molina-Almela

Subjects
Medicine
Abstract

Objective The main study objective was to determine how giant cell arteritis (GCA) is diagnosed in our clinical practice and whether the EULAR recommendations have influenced the diagnostic procedures used.Methods ARTEritis of the Rheumatology Spanish Society -Sociedad Española de Reumatología (ARTESER) is a multicentre observational retrospective study conducted in 26 hospitals with support from the Spanish Society of Rheumatology. All patients diagnosed with GCA between 1 June 2013 and 29 March 2019 were included. The gold standard for the diagnosis of GCA was the judgement of the physician in charge, according to clinical criteria, supported by data available from laboratory tests, imaging studies (ultrasound, positron emission tomography (PET) and MRI/CT angiography) and temporal artery biopsy (TAB) when available.Results We included 1675 patients with GCA (mean age±SD (76.9±8.1) years, 1178 women (70.3%)). Of these, 776 patients had a positive TAB (46.3%), 503 (30.0%) positive ultrasound, 245 positive PET (14.6%) and 64 positive MRI/CT angiography (3.8%). These percentages changed substantially over the study. From 2013 to 2019, the use of ultrasound in diagnosis grew from 25.8% to 52.9% and PET from 12.3% to 19.6%, while use of TAB decreased from 50.3% to 33.3%.Conclusions Biopsy was the most widely used diagnostic test for confirming GCA, but use of imaging as a diagnostic tool has grown in recent years. Following publication of the 2018 EULAR recommendations, ultrasound has displaced biopsy as the first-line diagnostic test; TAB was performed in a third and PET in a fifth of cases.

Published
2022
Full Text
View/download PDF

13. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Author

Antonio Julià, María López-Lasanta, Francisco Blanco, Antonio Gómez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz García Vivar, Jordi Monfort, Simón Sánchez-Fernández, Isidoro González, Mercedes Alperi, Raúl Castellanos-Moreira, Antonio Fernández-Nebro, César Díaz-Torné, Núria Palau, Raquel Lastra, Jordi Lladós, Raimon Sanmartí, and Sara Marsal

Subjects
Rheumatoid arthritis, Treatment response, Anti-TNF therapy, Autoantibodies, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.

Published
2021
Full Text
View/download PDF

14. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Author

Antonio Julià, Antonio Gómez, María López-Lasanta, Francisco Blanco, Alba Erra, Antonio Fernández-Nebro, Antonio Juan Mas, Carolina Pérez-García, Ma Luz García Vivar, Simón Sánchez-Fernández, Mercedes Alperi-López, Raimon Sanmartí, Ana María Ortiz, Carlos Marras Fernandez-Cid, César Díaz-Torné, Estefania Moreno, Tianlu Li, Sergio H. Martínez-Mateu, Devin M. Absher, Richard M. Myers, Jesús Tornero Molina, and Sara Marsal

Subjects
Rheumatoid arthritis, TNF inhibitors, Treatment response, Epigenetics, DNA methylation, Medicine, Medicine (General), R5-920
Abstract

Summary: Background: Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease of the joints that has been associated with variation in the peripheral blood methylome. In this study, we aim to identify epigenetic variation that is associated with the response to tumor necrosis factor inhibitor (TNFi) therapy. Methods: Peripheral blood genome-wide DNA methylation profiles were analyzed in a discovery cohort of 62 RA patients at baseline and at week 12 of TNFi therapy. DNA methylation of individual CpG sites and enrichment of biological pathways were evaluated for their association with drug response. Using a novel cell deconvolution approach, altered DNA methylation associated with TNFi response was also tested in the six main immune cell types in blood. Validation of the results was performed in an independent longitudinal cohort of 60 RA patients. Findings: Treatment with TNFi was associated with significant longitudinal peripheral blood methylation changes in biological pathways related to RA (FDR

Published
2022
Full Text
View/download PDF

15. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

Author

Torrente-Segarra, Vicenç, Salman-Monte, Tarek C., Rúa-Figueroa, Íñigo, del Campo, Víctor, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Olivé-Marqués, Alejandro, Mouriño-Rodríguez, Coral, Horcada, Loreto, Bohórquez, Cristina, Montilla, Carlos, Salgado, Eva, Díez-Álvarez, Elvira, Blanco, Ricardo, Andreu, José Luis, Fernández-Berrizbeitia, Olaia, Expósito, Lorena, Gantes, Marian, Hernández-Cruz, Blanca, Pecondón-Español, Ángela, Lozano-Rivas, Nuria, Bonilla, Gema, Lois Iglesias, Ana, Rubio-Muñoz, Paula, Ovalles, Juan, Tomero, Eva, Boteanu, Alina, Narvaez, Javier, Freire, Mercedes, Vela, Paloma, Quevedo-Vila, Víctor, Juan Mas, Antonio, Muñoz-Fernández, Santiago, Raya, Enrique, Moreno, Mireia, Velloso-Feijoo, ML, Soler, Gregorio, Vázquez-Rodríguez, Tomás Ramón, and Pego-Reigosa, José M.

Published
2020
Full Text
View/download PDF

16. Valoración del riesgo de fractura en población general en España mediante el algoritmo FRAX®: Estudio EPISER2016

Author

Silva-Fernández, Lucía, Sivera, Francisca, Quilis Martí, Neus, Blanco, Francisco J., Pérez Ruiz, Fernando, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Val del Amo, Natividad, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Gandía Martínez, Myriam, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Gómez-Vaquero, Carmen, Fábregas-Canales, Dolores, Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Published
2020
Full Text
View/download PDF

20. Prevalence of Rheumatic Diseases in Adult Population in Spain (EPISER 2016 Study): Aims and Methodology

Author

Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Silva-Fernández, Lucía, Sivera, Francisca, Blanco, Francisco J., Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis Martí, Neus, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Amo, Natividad del Val, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Ruiz Tudela, María del Mar, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Díaz-González, Federico, and Bustabad, Sagrario

Published
2019
Full Text
View/download PDF

21. Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodología

Author

Seoane-Mato, Daniel, Sánchez-Piedra, Carlos, Silva-Fernández, Lucía, Sivera, Francisca, Blanco, Francisco J., Pérez Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis Martí, Neus, Cortés Verdú, Raúl, Antón-Pagés, Fred, Quevedo Vila, Víctor, Garrido Courel, Laura, del Amo, Natividad del Val, Paniagua Zudaire, Inmaculada, Añez Sturchio, Gustavo, Medina Varo, Fermín, Ruiz Tudela, María del Mar, Romero Pérez, Antonio, Ballina, Javier, Brandy García, Anahy, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, González Álvarez, Beatriz, Casas Hernández, Laura, Álvarez Reyes, Fátima, Delgado Sánchez, Mónica, Martínez Dubois, Cristina, Sánchez-Fernández, Simón Ángel, Rojas Vargas, Luisa Marena, García Morales, Paula Virginia, Olivé, Alejandro, Rubio Muñoz, Paula, Larrosa, Marta, Navarro Ricos, Noemí, Graell Martín, Eduard, Chamizo, Eugenio, Chaves Chaparro, Lara, Rojas Herrera, Sara, Pons Dolset, Jordi, Polo Ostariz, Miguel Ángel, Ruiz-Alejos Garrido, Susana, Macía Villa, Cristina, Cruz Valenciano, Ana, González Gómez, María Luisa, Morcillo Valle, Mercedes, Palma Sánchez, Deseada, Moreno Martínez, María José, Mayor González, Marta, Atxotegi Sáenz de Buruaga, Joana, Urionagüena Onaindia, Irati, Blanco Cáceres, Boris Anthony, Díaz-González, Federico, and Bustabad, Sagrario

Published
2019
Full Text
View/download PDF

22. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study

Author

López-Medina, Clementina, primary, Calvo-Gutiérrez, Jerusalem, additional, Ábalos-Aguilera, M Carmen, additional, Cepas, Francisco, additional, Plasencia-Rodríguez, Chamaida, additional, Martínez-Feito, Ana, additional, Balsa, Alejandro, additional, Faré-García, Regina, additional, Juan-Mas, Antoni, additional, Ruiz-Esquide, Virginia, additional, Sainz, Luis, additional, Díaz-Torné, César, additional, Godoy-Navarrete, Francisco Javier, additional, Añón-Oñate, Isabel, additional, Mena-Vázquez, Natalia, additional, Manrique-Arija, Sara, additional, Moreno-García, Marina Soledad, additional, Ortega-Castro, Rafaela, additional, and Escudero-Contreras, Alejandro, additional

Published
2024
Full Text
View/download PDF

27. Evaluation of the impact of nursing clinics in the rheumatology services

Author

Muñoz-Fernández, Santiago, Aguilar, Ma Dolores, Rodríguez, Amparo, Almodóvar, Raquel, Cano-García, Laura, Gracia, Luís Antonio, Román-Ivorra, José A., Rodríguez, J. Ramón, Navío, Teresa, Lázaro, Pablo, Alegre-López, Javier, Alegre-Sancho, Juan José, Belzunegui-Otano, Joaquín, Bermúdez Torrente, Alberto, Bustabad Reyes, Sagrario, Calvo-Catalá, Javier, Campos-Esteban, José, Carbonell Jorda, Amelia, Castro-Oreiro, Sonia, Cerdá-Gabaroi, Dacia, Collantes-Estevez, Eduardo, Corteguera Coro, Montserrat, Espadaler Poch, Lluis, Fernández-Carballido, Cristina, Fernández Nebro, Antonio, Flores Torre, Manuel, García de Vicuña, Rosario, García Vivar, Mª Luz, Gómez España, Mª Victoria, Fortea, Sandra, Juan Mas, Antonio, Larrosa-Padró, Marta, Manero Ruiz, Javier, Martín-Mola, Emilio, Mateo-Bernardo, Isabel, Moya-Alvarado, Patricia, Noguera-Pons, José Raúl, Nolla Soléc, Joan Miquel, Peiró Callizo, Enriqueta, Pérez-Sandoval, Trinidad, Pina Pérez, Francisca, Del Pino Montes, Javier, Polo-Ostariz, Miguel Ángel, Rodríguez Heredia, José Manuel, Rodríguez Lozano, Carlos, Alcañiz, Cristina Patricia, Romero-Yuste, Susana, Roselló-Pardo, Rosa, Rusiñol-Badals, María, Sampedro-Álvarez, Juana, Sánchez-Atrio, Ana Isabel, Sánchez-Andrade Fernández, Amalia, Torre Alonso, Juan Carlos, Valero-Expósito, Marta, Vázquez-Díaz, Mónica, Veiga-Cabello, Raúl, and SCORE Working Group

Published
2016
Full Text
View/download PDF

28. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients

Author

Santos Castañeda, Lucía Martínez-Costa, Emma Beltrán, María Álvarez del Buergo, L Domínguez-Casas, Miguel A. González-Gay, Ruth López-González, Esteban Rubio-Romero, Ángel García-Aparicio, Ricardo Blanco, L. Sanchez-Bilbao, N. Vegas-Revenga, José L. Hernández, David Díaz-Valle, Antonio Juan Mas, R. Demetrio-Pablo, Ana Blanco, O. Maíz, and Vanesa Calvo-Río

Subjects
Adult, Male, medicine.medical_specialty, Corneal inflammation, Etanercept, Biological Factors, 03 medical and health sciences, Psoriatic arthritis, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Rheumatology, Internal medicine, medicine, Adalimumab, Humans, 030212 general & internal medicine, Corneal Ulcer, Aged, Aged, 80 and over, 030203 arthritis & rheumatology, business.industry, Middle Aged, medicine.disease, Infliximab, Anesthesiology and Pain Medicine, chemistry, Rheumatoid arthritis, Female, business, Scleritis, medicine.drug
Abstract

Purpose We assessed the efficacy and safety of biologic therapy in severe and refractory Peripheral Ulcerative Keratitis (PUK). Design Open-label multicenter study of biologic-treated patients with severe PUK refractory to conventional immunosuppressive drugs. Subjects We studied 34 patients (44 affected eyes) (24 women/10 men; mean age, 55.26±17.4 years). PUK was associated with a well-defined condition in 29 of them (rheumatoid arthritis [n = 20], psoriatic arthritis [n = 2], inflammatory bowel disease [n = 2], Behcet disease [n = 1], granulomatosis with polyangiitis [n = 1], microscopic polyangiitis [n = 1], systemic lupus erythematosus [n = 1] and axial spondyloarthritis [n = 1]). Besides topical and oral systemic glucocorticoids, patients had received: methylprednisolone pulses [n = 9], and conventional immunosuppressive drugs, mainly methotrexate [n = 18], and leflunomide [n = 7]. Eleven patients had required ocular surgery prior to biologic therapy. Methods Following biologic therapy, baseline main outcomes were compared with those found at 1st week, 1st and 6th months and 1st year. Main outcome measures Efficacy and safety of biologic therapy. Efficacy was analyzed by the assessment of corneal inflammation (corneal thinning, central keratolysis and ocular perforation); other causes of ocular surface inflammation (scleritis, episcleritis); intraocular inflammation (uveitis); visual acuity and glucocorticoid sparing effect. Results The first biologic agents used were anti-TNFα drugs (n = 25); adalimumab (n = 16), infliximab (n = 8), etanercept (n = 1), and non-TNFα agents (n = 9); rituximab (n = 7), tocilizumab (n = 1) belimumab (n = 1) and abatacept (n = 1). During the follow-up, switching to a second biologic agent was required in 12 of the 25 (48%) patients treated with anti-TNFα drugs. However, no switching was required in those undergoing biologic therapy different from anti-TNFα agents. The main outcome variables showed a rapid and maintained improvement after a mean follow-up of 23.7 ± 20 months. Major adverse effects were tachyphylaxis, relapsing respiratory infections, supraventricular tachycardia, pulmonary tuberculosis and death, one each. Conclusions Biologic therapy is effective and relatively safe in patients with severe and refractory PUK. Non-anti-TNFα agents appear to be effective in these patients.

Published
2020
Full Text
View/download PDF

29. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Author

Juliá, Antonio, Gómez, Antonio, López-Lasanta, María, Blanco García, Francisco J, Erra, Alba, Fernández-Nebro, Antonio, Juan Mas, Antonio, Pérez-García, Carolina, García Vivar, María Luz, Sánchez-Fernández, Simón, Alperi-López, Mercedes, Sanmartí, Raimon, Ortiz, Ana María, Marras Fernández-Cid, Carlos, Díaz-Torné, César, Moreno, Estefanía, Li, Tianlu, Martínez-Mateu, Sergio H., Absher, Devin M., Myers, Richard M., Tornero Molina, Jesús, Marsal, Sara, Juliá, Antonio, Gómez, Antonio, López-Lasanta, María, Blanco García, Francisco J, Erra, Alba, Fernández-Nebro, Antonio, Juan Mas, Antonio, Pérez-García, Carolina, García Vivar, María Luz, Sánchez-Fernández, Simón, Alperi-López, Mercedes, Sanmartí, Raimon, Ortiz, Ana María, Marras Fernández-Cid, Carlos, Díaz-Torné, César, Moreno, Estefanía, Li, Tianlu, Martínez-Mateu, Sergio H., Absher, Devin M., Myers, Richard M., Tornero Molina, Jesús, and Marsal, Sara

Abstract

[Abstract] Background: Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease of the joints that has been associated with variation in the peripheral blood methylome. In this study, we aim to identify epigenetic variation that is associated with the response to tumor necrosis factor inhibitor (TNFi) therapy. Methods: Peripheral blood genome-wide DNA methylation profiles were analyzed in a discovery cohort of 62 RA patients at baseline and at week 12 of TNFi therapy. DNA methylation of individual CpG sites and enrichment of biological pathways were evaluated for their association with drug response. Using a novel cell deconvolution approach, altered DNA methylation associated with TNFi response was also tested in the six main immune cell types in blood. Validation of the results was performed in an independent longitudinal cohort of 60 RA patients. Findings: Treatment with TNFi was associated with significant longitudinal peripheral blood methylation changes in biological pathways related to RA (FDR<0.05). 139 biological functions were modified by therapy, with methylation levels changing systematically towards a signature similar to that of healthy controls. Differences in the methylation profile of T cell activation and differentiation, GTPase-mediated signaling, and actin filament organization pathways were associated with the clinical response to therapy. Cell type deconvolution analysis identified CpG sites in CD4+T, NK, neutrophils and monocytes that were significantly associated with the response to TNFi. Interpretation: Our results show that treatment with TNFi restores homeostatic blood methylation in RA. The clinical response to TNFi is associated to methylation variation in specific biological pathways, and it involves cells from both the innate and adaptive immune systems.

Published
2022

31. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

Author

Silva-Díaz M, Blanco FJ, Quevedo Vila V, Seoane-Mato D, Pérez-Ruiz F, Juan-Mas A, Pego-Reigosa JM, Narváez J, Quilis N, Cortés R, Romero Pérez A, Fábregas Canales D, Font Gayá T, Bordoy Ferrer C, Prado-Galbarro FJ, Sánchez-Piedra C, Díaz-González F, and Bustabad-Reyes S

Subjects
Phenotypes, Osteoarthritis, Prevalence, Spine
Abstract

OBJECTIVE: Axial osteoarthritis (OA) is a common cause of back and neck pain, however, few studies have examined its prevalence. The aim was to estimate the prevalence and the characteristics of symptomatic axial OA in Spain. METHODS: EPISER2016 is a cross-sectional multicenter population-based study of people aged 40 years or older. Subjects were randomly selected using multistage stratified cluster sampling. Participants were contacted by telephone to complete rheumatic disease screening questionnaires. Two phenotypes were analyzed, patients with Non-exclusive axial OA (NEA-OA) and Exclusive axial OA (EA-OA). To calculate the prevalence and its 95% confidence interval (CI), the sample design was considered and weighting was calculated according to age, sex and geographic origin. RESULTS: Prevalence of NEA-OA by clinical or clinical-radiographic criteria was 19.17% (95% CI: 17.82-20.59). The frequency of NEA-OA increased with age (being 3.6 times more likely in patients aged 80 s or more than in those between 40 and 49 years) and body mass index. It was significantly more frequent in women, as well as in the center of Spain. It was less frequent in those with a higher level of education. Lumbar OA was more frequent than cervical OA. This difference grew with increasing age and was not associated with gender. It was also greater in overweight and obese subjects. CONCLUSIONS: This is the first study on the prevalence of axial OA phenotypes in Europe describing the associated socio-demographic, anthropometric, and lifestyle variables.

Published
2022

33. Diffuse idiopathic skeletal hyperostosis in a young woman treated with isotretinoin

Author

Mónica Ibáñez Barceló, Ana Estremera Rodrigo, Antonio Juan Mas, and Inmaculada Ros Vilamajó

Subjects
medicine.medical_specialty, business.industry, General Medicine, medicine.disease, Cervical spine, Dermatology, Rheumatology, Relevant feature, Medicine, business, Isotretinoin, Acne, Diffuse Idiopathic Skeletal Hyperostosis, medicine.drug
Abstract

We present the case of a 36-year-old woman with diffuse idiopathic skeletal hyperostosis especially at cervical spine since she was 29 years old. The only relevant feature was the use of isotretinoin at regular doses in the past for severe acne.

Published
2022
Full Text
View/download PDF

34. Seven chain adaptive immune receptor repertoire analysis in rheumatoid arthritis: association to disease and clinically relevant phenotypes

Author

Aterido, Adria, primary, Lopez-Lasanta, Maria, additional, Blanco, Francisco, additional, Juan-Mas, Antonio, additional, Garcia-Vivar, Maria Luz, additional, Erra, Alba, additional, Perez-Garcia, Carolina, additional, Sanchez-Fernandez, Simon Angel, additional, Sanmarti, Raimon, additional, Fernandez-Nebro, Antonio, additional, Alperi-Lopez, Mercedes, additional, Tornero, Jesus, additional, Ortiz, Ana Maria, additional, Fernandez-Cid, Carlos Marras, additional, Palau, Nuria, additional, Pan, Wenjing, additional, Byrne-Steele, Miranda, additional, Starenki, Dmytro, additional, Weber, Daniel, additional, Rodriguez-Nunez, Ivan, additional, Han, Jian, additional, Myers, Richard M, additional, Marsal, Sara, additional, and Julia, Antonio, additional

Published
2021
Full Text
View/download PDF

35. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Author

Alba Erra, Sara Marsal, Jordi Monfort, Antonio Fernández-Nebro, Raimon Sanmartí, R. M. Lastra, María L. García Vivar, Raul Castellanos-Moreira, Francisco J. Blanco, Simón Ángel Sánchez-Fernández, I. González, Mercedes Alperi, Antonio Julià, Núria Palau, Cesar Diaz-Torne, Isabel Haro, María López-Lasanta, Antonio Juan Mas, Jordi Lladós, Antonio Gómez, Institut Català de la Salut, [Julià A, López-Lasanta M, Gómez A, Erra A, Palau N, Lastra R, Lladós J, Marsal S] Grup de Recerca en Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Blanco F] Rheumatology Department, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain. [Haro I] Unitat de Síntesi i Aplicacions Biomèdiques de Pèptids, IQAC-CSIC, Barcelona, Spain. [Mas AJ] Rheumatology Department, Hospital Universitario Son Llàtzer, Mallorca, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Oncology, Diseases of the musculoskeletal system, Autoanticossos, Treatment response, Arthritis, Rheumatoid, Clinical rheumatology and osteoporosis, 0302 clinical medicine, Medicine, Orthopedics and Sports Medicine, Prospective Studies, Other subheadings::/therapeutic use [Other subheadings], Prospective cohort study, biology, Anti-TNF therapy, enfermedades musculoesqueléticas::artropatías::artritis::artritis reumatoide [ENFERMEDADES], Rheumatoid arthritis, Antibody, Anti-tumor necrosis factor therapy, Musculoskeletal Diseases::Joint Diseases::Arthritis::Arthritis, Rheumatoid [DISEASES], Research Article, medicine.medical_specialty, Artritis reumatoide - Tractament, Antiinflamatoris - Ús terapèutic, Peptides, Cyclic, aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::autoanticuerpos::factor reumatoide [COMPUESTOS QUÍMICOS Y DROGAS], 03 medical and health sciences, Rheumatology, Rheumatoid Factor, Internal medicine, Humans, Rheumatoid factor, Retrospective Studies, Autoantibodies, 030203 arthritis & rheumatology, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinflamatorios [COMPUESTOS QUÍMICOS Y DROGAS], business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], Autoantibody, Rheumatoid arthritis antibodies, Retrospective cohort study, medicine.disease, Anti-Tumor Necrosis Factor Therapy, 030104 developmental biology, RC925-935, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents [CHEMICALS AND DRUGS], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Autoantibodies::Rheumatoid Factor [CHEMICALS AND DRUGS], biology.protein, Tumor Necrosis Factor Inhibitors, business
Abstract

Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA., This project was supported by UCB Pharma. The funders had no role in the study design, data analysis, data interpretation or writing the manuscript.

Published
2021

36. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

Author

Silva-Diaz M, Blanco F, Vila V, Seoane-Mato D, Perez-Ruiz F, Juan-Mas A, Pego-Reigosa J, Narvaez J, Quilis N, Cortes R, Perez A, Canales D, Gaya T, Ferrer C, Prado-Galbarro F, Sanchez-Piedra C, Diaz-Gonzalez F, Bustabad-Reyes S, and Working Grp Proyecto EPISER2016

Subjects
Phenotypes, Osteoarthritis, Prevalence, Spine
Abstract

Objective Axial osteoarthritis (OA) is a common cause of back and neck pain, however, few studies have examined its prevalence. The aim was to estimate the prevalence and the characteristics of symptomatic axial OA in Spain. Methods EPISER2016 is a cross-sectional multicenter population-based study of people aged 40 years or older. Subjects were randomly selected using multistage stratified cluster sampling. Participants were contacted by telephone to complete rheumatic disease screening questionnaires. Two phenotypes were analyzed, patients with Non-exclusive axial OA (NEA-OA) and Exclusive axial OA (EA-OA). To calculate the prevalence and its 95% confidence interval (CI), the sample design was considered and weighting was calculated according to age, sex and geographic origin. Results Prevalence of NEA-OA by clinical or clinical-radiographic criteria was 19.17% (95% CI: 17.82-20.59). The frequency of NEA-OA increased with age (being 3.6 times more likely in patients aged 80 s or more than in those between 40 and 49 years) and body mass index. It was significantly more frequent in women, as well as in the center of Spain. It was less frequent in those with a higher level of education. Lumbar OA was more frequent than cervical OA. This difference grew with increasing age and was not associated with gender. It was also greater in overweight and obese subjects. Conclusions This is the first study on the prevalence of axial OA phenotypes in Europe describing the associated socio-demographic, anthropometric, and lifestyle variables.

Published
2021

37. Seven Chain Adaptive Immune Receptor Repertoire Analysis in Rheumatoid Arthritis: Association to Disease and Clinically Relevant Phenotypes

Author

Raimon Sanmartí, Carlos Marras Fernandez-Cid, Jian Han, Iván Rodríguez-Núñez, Antonio Julià, Francisco J. Blanco, Antonio Juan-Mas, Adrià Aterido, María Luz García-Vivar, Carolina Pérez-García, Richard M. Myers, Daniel Weber, Simón Ángel Sánchez-Fernández, Sara Marsal, Mercedes Alperi-López, Alba Erra, Ana M. Ortiz, Dmytro Starenki, Antonio Fernández-Nebro, María López-Lasanta, Wenjing Pan, Jesús Tornero, Miranda Byrne-Steele, and Núria Palau

Subjects
History, Polymers and Plastics, B-cell receptor, T-cell receptor, breakpoint cluster region, Immune receptor, Human leukocyte antigen, Biology, Acquired immune system, Industrial and Manufacturing Engineering, medicine.anatomical_structure, Antigen, Immunology, medicine, Business and International Management, B cell
Abstract

Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease characterized by a defective adaptive immune receptor repertoire (AIRR) that fails to distinguish self from non-self antigens. The AIRR is vast, encompassing four T cell receptor (TCR) and three B cell receptor (BCR) chains, each of which displays an extraordinary amino acid sequence variability in the antigen-binding site. How the concerted action of T and B cell clones is associated with the development and clinical evolution of immune-mediated diseases is still not known. Using a new immunosequencing technology that allows the unbiased amplification of the seven receptor chains, we conducted an in-depth quantitative analysis of the seven-receptor chain variability in RA. Compared to healthy controls, the AIRR in RA was found to be characterized by a lower BCR diversity, the depletion of highly similar BCR clones, an isotype-specific signature as well as a skewed IGL chain and gene segment usage. A predictor based on quantitative multi-chain AIRR information was able to accurately predict disease, including the elusive seronegative subset of RA patients. AIRR features of the seven immune receptor chains were also different between patients with distinct clinically relevant phenotypes. Incorporating HLA variation data, we were able to identify the TCR clones that are specifically associated with the main disease risk variants. The longitudinal analysis of the AIRR revealed that treatment with Tumor Necrosis Factor (TNF) inhibitors selectively restores the diversity of B cell clones in RA patients by reducing the frequency of clones with a similar biochemical profile. The biochemical properties of the TNFi-modulated clones were also found to differ between responders and non-responders, supporting a different antigenic reactivity in the B cell compartment of these two groups of RA patients. Our comprehensive analysis of the TCR and BCR repertoire reveals a complex T and B cell architecture in RA, and provides the basis for precision medicine strategies based on the highly informative features of the adaptive immune response.

Published
2021
Full Text
View/download PDF

38. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

Author

Martín-Martínez MA, Castañeda S, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, Sánchez-Costa JT, Belmonte-López MA, Tornero-Molina J, Santos-Rey J, Sánchez González CO, Quesada E, Moreno-Gil MP, Cobo-Ibáñez T, Pinto-Tasnde JA, Babío-Herráez J, Bonilla G, Juan-Mas A, Manero-Ruiz FJ, Romera-Baurés M, Bachiller-Corral J, Chamizo-Carmona E, Uriarte-Ecenarro M, Barbadillo C, Fernández-Carballido C, Aurrecoechea E, Möller-Parrera I, Llorca J, González-Gay MA, and CARMA Project Collaborative Group

Subjects
PsA, cardiovascular disease, cohort study, incidence, RA, mortality, AS
Abstract

OBJECTIVES: To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up. METHODS: This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n = 775), AS (n = 738) and PsA (n = 721), and individuals without CIRD (n = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain. Descriptive analyses were performed for the CV mortality at 5 years. The Systematic COronary Risk Evaluation (SCORE) function at 5 years was calculated to determine the expected risk of CV mortality. Poisson models were used to estimate the incidence rates of the first CVE. Hazard ratios of the risk factors involved in the development of the first CVE were evaluated using the Weibull proportional hazard model. RESULTS: Overall, 2382 subjects completed the follow-up visit at 5 years. Fifteen patients died due to CVE. CV deaths observed in the CIRD cohort were lower than that predicted by SCORE risk charts. The highest incidence rate of CVE [7.39 cases per 1000 person-years (95% CI 4.63, 11.18)] was found in PsA patients. However, after adjusting for age, sex and CV risk factors, AS was the inflammatory disease more commonly associated with CVE at 5 years [hazard ratio 4.60 (P =0.02)], compared with those without CIRD. CONCLUSIONS: Cardiovascular mortality in patients with CIRD at 5 years of follow-up is lower than estimated. Patients with AS have a higher risk of developing a first CVE after 5 years of follow-up.

Published
2021

40. Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry

Author

De Miguel, E, Sanchez-Costa, JT, Narvaez, J, Gonzalez-Gay, M, Garrido-Punal, N, Estrada-Alarcon, PV, Hernandez-Rodriguez, I, Fernandez-Fernandez, E, Silva-Diaz, MT, Valero-Jaimes, JA, Gonzalez-Fernandez, I, Sanchez, J, Lluch, J, Galindez-Agirregoikoa, E, Mendizabal-Mateos, J, Rodriguez, LR, Garcia, JL, Munoz, A, Castaneda, S, Moya, P, Moran-Alvarez, P, Navarro-Angeles, VA, Calvet-Fontova, J, Casafont, I, Ortiz-Sanjuan, F, Labrada-Arrabal, S, Campos-Fernandez, C, Alcalde-Villar, M, Juan-Mas, A, and Blanco, R

Published
2021

41. Prevalence of Symptomatic Axial Osteoarthritis Phenotypes in Spain and Associated Socio-Demographic, Anthropometric, and Lifestyle Variables

Author

Francisco Javier Prado-Galbarro, Javier Narváez, Federico Díaz-González, Carolina Bordoy Ferrer, Sagrario Bustabad-Reyes, Dolores Fábregas Canales, Raúl Cortés, Maite Silva-Díaz, Daniel Seoane-Mato, Víctor Quevedo Vila, Teresa Font Gayá, Neus Quilis, Antonio Romero Pérez, Francisco J. Blanco, Fernando Perez-Ruiz, Antonio Juan-Mas, Carlos Sánchez-Piedra, José M. Pego-Reigosa, Consejo Superior de Investigaciones Científicas (España), Conferencia de Rectores de las Universidades Españolas, Celgene, Gebro Pharma, Merck, Sharp & Dohme, Pfizer, Sanofi, Plan Nacional de I+D+i (España), Instituto de Salud Carlos III, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)

Subjects
medicine.medical_specialty, Immunology, Population, Overweight, Rheumatology, Internal medicine, Osteoarthritis, medicine, Prevalence, Immunology and Allergy, Humans, education, Life Style, Neck pain, education.field_of_study, business.industry, Anthropometry, Osteoarthritis, Knee, Confidence interval, Spine, Phenotypes, Cross-Sectional Studies, Phenotype, Spain, Cluster sampling, Female, medicine.symptom, business, Body mass index, Demography
Abstract

Epidemiology of RMD Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG [Abstract] Objective. Axial osteoarthritis (OA) is a common cause of back and neck pain, however, few studies have examined its prevalence. The aim was to estimate the prevalence and the characteristics of symptomatic axial OA in Spain. Methods. EPISER2016 is a cross-sectional multicenter population-based study of people aged 40 years or older. Subjects were randomly selected using multistage stratified cluster sampling. Participants were contacted by telephone to complete rheumatic disease screening questionnaires. Two phenotypes were analyzed, patients with Non-exclusive axial OA (NEA-OA) and Exclusive axial OA (EA-OA). To calculate the prevalence and its 95% confidence interval (CI), the sample design was considered and weighting was calculated according to age, sex and geographic origin. Results. Prevalence of NEA-OA by clinical or clinical-radiographic criteria was 19.17% (95% CI: 17.82–20.59). The frequency of NEA-OA increased with age (being 3.6 times more likely in patients aged 80 s or more than in those between 40 and 49 years) and body mass index. It was significantly more frequent in women, as well as in the center of Spain. It was less frequent in those with a higher level of education. Lumbar OA was more frequent than cervical OA. This difference grew with increasing age and was not associated with gender. It was also greater in overweight and obese subjects. Conclusions. This is the first study on the prevalence of axial OA phenotypes in Europe describing the associated socio-demographic, anthropometric, and lifestyle variables. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. EPISER2016 was supported by Celgene, Gebro Pharma, Merck Sharp & Dohme in Spain, Pfizer, and Sanofi-Aventis, none of whom had any role in the study design, data collection, data analysis, interpretation, or writing of this manuscript. MS was financed via the Rio Hortega Contract—Health Research Fund (CM17/00101), the Sanitary Research Fund integrated in the National Plan of Scientific Program, Technological Development and Innovation 2013–2016 and funded by the ISCIII-Subdirectorate General Evaluation and Promotion of Research-European Regional Development Fund (ERDF) "A way of making Europe"

Published
2021

42. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Author

Julià, Antonio, López-Lasanta, María, Blanco, Francisco, Gómez, Antonio, Haro Villar, Isabel, Juan Mas, Antonio, Erra, Alba, García Vivar, M. Luz, Monfort, Jordi, Sánchez-Fernández, Simón, González, Isidoro, Alperi, Mercedes, Castellanos-Moreira, Raul, Fernández-Nebro, Antonio, Díaz-Torné, César, Palau, Núria, Lastra, Raquel, Lladós, Jordi, Sanmartí, Raimon, Marsal, Sara, Julià, Antonio, López-Lasanta, María, Blanco, Francisco, Gómez, Antonio, Haro Villar, Isabel, Juan Mas, Antonio, Erra, Alba, García Vivar, M. Luz, Monfort, Jordi, Sánchez-Fernández, Simón, González, Isidoro, Alperi, Mercedes, Castellanos-Moreira, Raul, Fernández-Nebro, Antonio, Díaz-Torné, César, Palau, Núria, Lastra, Raquel, Lladós, Jordi, Sanmartí, Raimon, and Marsal, Sara

Abstract

Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.

Published
2021

43. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

Author

Silva-Díaz, María T., Blanco García, Francisco J, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez-Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero-Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Prado-Galbarro, Francisco Javier, Sánchez-Piedra, Carlos, Díaz-González, Federico, Bustabad-Reyes, Sagrario, Silva-Díaz, María T., Blanco García, Francisco J, Quevedo Vila, Víctor, Seoane-Mato, Daniel, Pérez-Ruiz, Fernando, Juan-Mas, Antonio, Pego-Reigosa, José M., Narváez, Javier, Quilis, Neus, Cortés, Raúl, Romero-Pérez, Antonio, Fábregas Canales, Dolores, Font Gayá, Teresa, Bordoy Ferrer, Carolina, Prado-Galbarro, Francisco Javier, Sánchez-Piedra, Carlos, Díaz-González, Federico, and Bustabad-Reyes, Sagrario

Abstract

[Abstract] Objective. Axial osteoarthritis (OA) is a common cause of back and neck pain, however, few studies have examined its prevalence. The aim was to estimate the prevalence and the characteristics of symptomatic axial OA in Spain. Methods. EPISER2016 is a cross-sectional multicenter population-based study of people aged 40 years or older. Subjects were randomly selected using multistage stratified cluster sampling. Participants were contacted by telephone to complete rheumatic disease screening questionnaires. Two phenotypes were analyzed, patients with Non-exclusive axial OA (NEA-OA) and Exclusive axial OA (EA-OA). To calculate the prevalence and its 95% confidence interval (CI), the sample design was considered and weighting was calculated according to age, sex and geographic origin. Results. Prevalence of NEA-OA by clinical or clinical-radiographic criteria was 19.17% (95% CI: 17.82–20.59). The frequency of NEA-OA increased with age (being 3.6 times more likely in patients aged 80 s or more than in those between 40 and 49 years) and body mass index. It was significantly more frequent in women, as well as in the center of Spain. It was less frequent in those with a higher level of education. Lumbar OA was more frequent than cervical OA. This difference grew with increasing age and was not associated with gender. It was also greater in overweight and obese subjects. Conclusions. This is the first study on the prevalence of axial OA phenotypes in Europe describing the associated socio-demographic, anthropometric, and lifestyle variables.

Published
2021

44. POS0996 SIX-YEAR RESULTS FROM THE ESPERANZA COHORT: EVALUATION OF CLINICAL FEATURES, DISEASE ACTIVITY MEASURES AND TREATMENT ASPECTS IN AXIAL AND PERIPHERAL EARLY SPONDYLOARTHRITIS

Author

Tornero, C., primary, Navarro-Compán, V., additional, Joven-Ibáñez, B., additional, Almodovar, R., additional, Juanola-Roura, X., additional, Fernández-Carballido, C., additional, Quevedo-Abeledo, J. C., additional, Rosas, J., additional, Hernández, A., additional, Montilla-Morales, C. A., additional, Maneiro, J. R., additional, Juan-Mas, A., additional, Pinto Tasende, J. A., additional, Moreno, M., additional, Sanz, J., additional, Ruiz Jimeno, T., additional, Ladehesa Pineda, M. L., additional, and De Miguel, E., additional

Published
2021
Full Text
View/download PDF

45. OP0064 TOCILIZUMAB IN CRANIAL AND EXTRACRANIAL REFRACTORY GIANT CELL ARTERITIS: A MULTICENTER STUDY OF 312 CASES

Author

Sanchez-Bilbao, L., primary, Loricera, J., additional, Aldasoro, V., additional, Valdivieso-Achá, J. P., additional, Villa-Blanco, I., additional, Maiz, O., additional, Melero, R., additional, Moriano, C., additional, Sánchez, J., additional, De Miguel, E., additional, Perez-Pampín, E., additional, De Dios, J. R., additional, Nieto González, J. C., additional, Galíndez-Agirregoikoa, E., additional, Moya, P., additional, Sivera, F., additional, Andréu Sánchez, J. L., additional, Pinillos, V., additional, García-Valle, A., additional, Vela-Casasempere, P., additional, Alvarez-Rivas, N., additional, Revenga, M., additional, Manrique Arija, S., additional, Fernández-López, C., additional, Raya, E., additional, Hidalgo, C., additional, López-González, R., additional, Campos Fernández, C., additional, Juan-Mas, A., additional, Arca, B., additional, Rua-Figueroa, I., additional, Boquet, M. D., additional, García, A., additional, Gallego, A., additional, Salgado-Pérez, E., additional, González-Gay, M. A., additional, and Blanco, R., additional

Published
2021
Full Text
View/download PDF

47. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients

Author

Fernández-Díaz, Carlos, primary, Castañeda, Santos, additional, Melero-González, Rafael B, additional, Ortiz-Sanjuán, Francisco, additional, Juan-Mas, Antonio, additional, Carrasco-Cubero, Carmen, additional, Casafont-Solé, Ivette, additional, Olivé, Alejandro, additional, Rodríguez-Muguruza, Samantha, additional, Almodóvar-González, Raquel, additional, Castellanos-Moreira, Raul, additional, Rodríguez-García, Sebastian C, additional, Aguilera-Cros, Clara, additional, Villa, Ignacio, additional, Ordóñez-Palau, Sergio, additional, Raya-Alvarez, Erique, additional, Morales-Garrido, Pilar, additional, Ojeda-García, Clara, additional, Moreno-Ramos, Manuel J, additional, Bonilla Hernán, María Gema, additional, Hernández Rodríguez, Iñigo, additional, López-Corbeto, Mireia, additional, Andreu, José L, additional, Jiménez de Aberásturi, Juan R D, additional, Ruibal-Escribano, Ana, additional, Expósito-Molinero, Rosa, additional, Pérez-Sandoval, Trinidad, additional, López-Robles, Ana María, additional, Carreira-Delgado, Patricia, additional, Mena-Vázquez, Natalia, additional, Urruticoechea-Arana, Ana, additional, Peralta-Ginés, Cilia, additional, Arboleya-Rodríguez, Luis, additional, Narváez García, F Javier, additional, Palma-Sánchez, Deseada, additional, Cervantes Pérez, Evelin C, additional, Maiz-Alonso, Olga, additional, Alvarez-Rivas, María N, additional, Fernández-Melón, Julia, additional, Vela Casasempere, Paloma, additional, Cabezas-Rodríguez, Ivan, additional, Castellvi-Barranco, Iván, additional, González-Montagut, Carmen, additional, Blanco-Madrigal, Juan, additional, Del Val-Del Amo, Natividad, additional, Fito, María C, additional, Rodríguez-Gómez, Manuel, additional, Salgado-Pérez, Eva, additional, García-Magallón, Blanca, additional, Hidalgo-Calleja, Cristina, additional, López-Sánchez, Ruben, additional, Fernández-Aguado, Sabela, additional, Fernández-López, Jesús C, additional, Castro-Oreiro, Sonia, additional, Serrano-García, Isabel, additional, García-Valle, Andrea, additional, Romero-Yuste, Susana, additional, Expósito-Pérez, Lorena, additional, Pérez-Albadalejo, Lorena, additional, García-Aparicio, Angel, additional, Quillis-Marti, Neus, additional, Bernal-Vidal, José A, additional, Loricera-García, Javier, additional, Hernández, José L, additional, González-Gay, Miguel A, additional, and Blanco, Ricardo, additional

Published
2020
Full Text
View/download PDF

49. SAT0075 ABATACEPT IN COMBINATION WITH METOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED TO INTERSTITIAL LUNG DISEASE: NATIONAL MULTICENTER STUDY OF 263 PATIENTS

Author

Fernández-Díaz, C., primary, Castañeda, S., additional, Melero, R., additional, Loricera, J., additional, Ortiz-Sanjuán, F., additional, Juan-Mas, A., additional, Carrasco-Cubero, C., additional, Rodriguéz-Muguruza, S., additional, Rodrigez-Garcia, S., additional, Castellanos-Moreira, R., additional, Almodovar, R., additional, Aguilera Cros, C., additional, Villa-Blanco, I., additional, Ordoñez, S., additional, Romero-Yuste, S., additional, Ojeda-Garcia, C., additional, Moreno, M., additional, Bonilla, G., additional, Hernández-Rodriguez, I., additional, Lopez Corbeto, M., additional, Andréu Sánchez, J. L., additional, Pérez Sandoval, T., additional, López Robles, A., additional, Carreira, P., additional, Mena-Vázquez, N., additional, Peralta-Ginés, C., additional, Urruticoechea-Arana, A., additional, Arboleya Rodríguez, L. M., additional, Narváez, J., additional, Palma Sanchez, D., additional, Maiz-Alonso, O., additional, Fernández-Leroy, J., additional, Cabezas-Rodriguez, I., additional, Castellví, I., additional, Ruibal-Escribano, A., additional, De Dios-Jiménez Aberásturi, J., additional, Vela-Casasempere, P., additional, González-Montagut Gómez, C., additional, Blanco, J. M., additional, Alvarez-Rivas, N., additional, Del-Val, N., additional, Rodíguez-Gómez, M., additional, Salgado-Pérez, E., additional, Fernández-López, C., additional, Cervantes Pérez, E. C., additional, Devicente-Delmas, A., additional, Garcia-Magallon, B., additional, Hidalgo, C., additional, Fernández, S., additional, García-Fernández, E., additional, López-Sánchez, R., additional, Castro, S., additional, Morales-Garrido, P., additional, García-Valle, A., additional, Expósito, R., additional, Exposito-Perez, L., additional, Pérez Albaladejo, L., additional, García-Aparicio, Á., additional, Blanco, R., additional, and González-Gay, M. A., additional

Published
2020
Full Text
View/download PDF

50. SAT0035 RESPONSE TO ABATACEPT OF DIFFERENT PATTERNS OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: NATIONAL MULTICENTER STUDY OF 263 PATIENTS

Author

Fernández-Díaz, C., primary, Castañeda, S., additional, Melero, R., additional, Loricera, J., additional, Ortiz-Sanjuán, F., additional, Juan-Mas, A., additional, Carrasco-Cubero, C., additional, Rodriguéz-Muguruza, S., additional, Rodrigez-Garcia, S., additional, Castellanos-Moreira, R., additional, Almodovar, R., additional, Aguilera Cros, C., additional, Villa-Blanco, I., additional, Ordoñez, S., additional, Romero-Yuste, S., additional, Ojeda-Garcia, C., additional, Moreno, M., additional, Bonilla, G., additional, Hernández-Rodriguez, I., additional, Lopez Corbeto, M., additional, Andréu Sánchez, J. L., additional, Pérez Sandoval, T., additional, López Robles, A., additional, Carreira, P., additional, Mena-Vázquez, N., additional, Peralta-Ginés, C., additional, Urruticoechea-Arana, A., additional, Arboleya Rodríguez, L. M., additional, Narváez, J., additional, Palma Sanchez, D., additional, Maiz-Alonso, O., additional, Fernández-Leroy, J., additional, Cabezas-Rodriguez, I., additional, Castellví, I., additional, Ruibal-Escribano, A., additional, De Dios-Jiménez Aberásturi, J., additional, Vela-Casasempere, P., additional, González-Montagut Gómez, C., additional, Blanco, J. M., additional, Alvarez-Rivas, N., additional, Del-Val, N., additional, Rodíguez-Gómez, M., additional, Salgado-Pérez, E., additional, Fernández-López, C., additional, Cervantes Pérez, E. C., additional, Devicente-Delmas, A., additional, Garcia-Magallon, B., additional, Hidalgo, C., additional, Fernández, S., additional, López-Sánchez, R., additional, García-Fernández, E., additional, Castro, S., additional, Morales-Garrido, P., additional, García-Valle, A., additional, Expósito, R., additional, Exposito-Perez, L., additional, Pérez Albaladejo, L., additional, García-Aparicio, Á., additional, González-Gay, M. A., additional, and Blanco, R., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results